Clinical trials: Nevirapine
Treatment Failure, HIV or AIDS, CD4 Cell Counts
Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity
The primary objective of this study is to compare the effectiveness of EFV-based regimens in HIV-1-infected patients who; (1) were previously allergic to NVP and stopped all ARV simultaneously; (2) were previously allergic to NVP…
- Trial name
- NCT01044810
- Testing
- Efavirenz-based regimens
- Where
- Thailand
- Volunteers
- 559 people
- Sponsor
- Bamrasnaradura Infectious Diseases Institute
HIV Infections
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
To evaluate the tolerance and immunologic and virologic effects of multidrug combinations of antiretrovirals in patients with HIV infection.
- Trial name
- NCT00002347
- Testing
- Saquinavir, Nevirapine, Zidovudine
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Parexel
HIV Infections
Pharmacokinetics Study on Nevirapine Resistance in Tanzania
Primary pharmacokinetics of single dose nevirapine the effect of single dose carbamazepine on the pk of single dose nevirapine resistance against nevirapine before and after.
- Trial name
- NCT00294892
- Testing
- carbamazepine and nevirapine, Nevirapine
- Where
- Tanzania
- Volunteers
- 144 people
- Sponsor
- Radboud University Medical Center
HIV Infections
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.
- Trial name
- NCT00002368
- Testing
- Nevirapine, Lamivudine
- Where
- 53 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients
The study aims to evaluate the changes in mitochondrial DNA (mDNA) by means of the mDNA/nuclearDNA (nDNA) ratio as a marker of mitochondrial toxicity following the interruption of nucleoside analogues.
- Trial name
- NCT00335686
- Testing
- Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h, Nevirapine (Viramune): 1 comp (200mg)/12h
- Where
- 24 sites in Spain
- Volunteers
- 67 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV Infections, Pregnancy
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby during delivery.
- Trial name
- NCT00000942
- Testing
- Nevirapine
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 1,244 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males
Study to determine the absorption of Nevirapine from different regions of the Gastro Intestinal tract.
- Trial name
- NCT02191189
- Testing
- Nevirapine suspension, into Enterion™ capsule, Nevirapine suspension
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
The purpose of this study is to see if it is safe and effective to give HIV-infected children and teens 1 of 4 anti-HIV drug combinations. Decreasing HIV levels in infected patients can slow down disease progression.
- Trial name
- NCT00001091
- Testing
- Ritonavir, Nelfinavir mesylate, Nevirapine
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Pregnancy
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers
To determine the bioavailability, pharmacokinetics, and short-term safety and tolerance of nevirapine in HIV-1 infected pregnant women and their newborns when nevirapine is given to the mother during active labor, and when their…
- Trial name
- NCT00000808
- Testing
- Nevirapine
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 49 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
AIDS, HIV Infections
Pediatric Nevirapine Resistance Study
This study is designed to test if a sequential protease-inhibitor (PI) - / nevirapine (NVP) -based regimen is effective for the treatment of HIV-infected children when previous NVP exposure has occurred as part of programs to…
- Trial name
- NCT00117728
- Testing
- nevirapine
- Where
- South Africa
- Volunteers
- 250 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hiv Infection With Antiretroviral Therapy Indication, CD4 Below 350/µL or Below 15%
Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients
The study will compare the immuno-virological efficacy, and safety, of a once daily antiretroviral combination (tenofovir + lamivudine + nevirapine) versus a twice daily association (fixed dose combination of…
- Trial name
- NCT00199979
- Testing
- Nevirapine
- Where
- France
- Volunteers
- 250 people
- Sponsor
- MEDEX
HIV Infections, Pregnancy
A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby during delivery.
- Trial name
- NCT00000869
- Testing
- Nevirapine
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 2,009 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
PRIMARY: To compare the effect of nevirapine versus placebo alone or in combination with zidovudine (AZT) on CD4 T-cell count and percentage after 3 and 6 months of treatment.
- Trial name
- NCT00002324
- Testing
- Nevirapine, Zidovudine
- Where
- 18 sites in United States
- Volunteers
- 250 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Durability of Nevirapine-Based Antiretroviral Regimen
Although nevirapine is used as an alternative to efavirenz for initial regimen in developed countries, nevirapine has still been a key antiretroviral drug in many resource-limited countries including Thailand due to its…
- Trial name
- NCT00703898
- Testing
- nevirapine
- Where
- Thailand
- Volunteers
- 140 people
- Sponsor
- Bamrasnaradura Infectious Diseases Institute
HIV Infections
Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort
The purpose of this study is to determine whether the three generic nevirapine-based antiretroviral regimens are effective in the treatment of Acquired immune deficiency syndrome .
- Trial name
- NCT00618176
- Testing
- Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP), Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Peking Union Medical College
HIV-1 Infection
Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
In resource-limited setting, concerns remain regarding the emergence of virologic failure and high-level drug resistance mutations (DRM) during WHO recommended first-line antiretroviral therapy (ART) with non-nucleoside reverse…
- Trial name
- NCT01772940
- Testing
- nevirapine, ritonavir-boosted Lopinavir, Tenofovir/emtricitabine
- Where
- Republic of the Congo
- Volunteers
- 425 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
HIV Infections
Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen.
- Trial name
- NCT00014937
- Testing
- lopinavir/ritonavir, lamivudine/zidovudine, efavirenz
- Where
- 37 sites in United States, Italy and 1 more
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
Study to determine the effects of 28 days of nevirapine treatment on the steady-state pharmacokinetics of amprenavir and of abacavir and to further evaluate the pharmacokinetics of nevirapine in combination with amprenavir and…
- Trial name
- NCT02182765
- Testing
- Nevirapine, Amprenavir, Abacavir
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients
Study to determine the effects of nevirapine on the steady state pharmacokinetics of rifabutin and to assess the steady state pharmacokinetics of nevirapine when given in combination with rifabutin
- Trial name
- NCT02184078
- Testing
- Nevirapine, Rifabutin
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
2NN & CHARM Long-Term Follow-up Study
It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
- Trial name
- NCT00127972
- Testing
- stavudine, lamivudine, nevirapine
- Where
- Australia
- Volunteers
- 763 people
- Sponsor
- International Antiviral Therapy Evaluation Center